Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00138357" target="_blank" >RIV/00216224:14110/24:00138357 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1017/S0266462324003702" target="_blank" >http://dx.doi.org/10.1017/S0266462324003702</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1017/S0266462324003702" target="_blank" >10.1017/S0266462324003702</a>
Alternative languages
Result language
angličtina
Original language name
Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic
Original language description
Immunotherapy is increasingly used in the treatment of metastatic lung cancer, with coverage provided by Czech public health insurance for specific indications. This study assesses the potential budgetary impact of implementing performance-based risk-sharing agreements (PBRSA) for immunotherapy. A retrospective analysis of 127 lung cancer patients treated with immunotherapy (including 42 receiving nivolumab) at the Masaryk Memorial Cancer Institute revealed discrepancies between real-world progression-free survival (PFS) and clinical trial data. Treatment costs varied significantly based on treatment success, with unsuccessful cases averaging EUR9,300 per patient and successful cases exceeding EUR29,700. A PBRSA model could shift up to 66% of costs for unsuccessful treatments to manufacturers, potentially funding additional patients. This study highlights the importance of PBRSA in addressing the economic challenges of high-cost therapies, improving affordability, and ensuring sustainable access for patients.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/LM2023049" target="_blank" >LM2023049: Czech National Node of the European Clinical Research Infrastructures Network</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů